CN105431162B - 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台 - Google Patents

用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台 Download PDF

Info

Publication number
CN105431162B
CN105431162B CN201480043222.XA CN201480043222A CN105431162B CN 105431162 B CN105431162 B CN 105431162B CN 201480043222 A CN201480043222 A CN 201480043222A CN 105431162 B CN105431162 B CN 105431162B
Authority
CN
China
Prior art keywords
peptide
isolated peptide
poly
nanoparticles
microparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201480043222.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN105431162A (zh
Inventor
亚历山大·S·波佩尔
尼兰贾·B·潘迪
艾萨克·李
乔丹·J·格林
朗·B·史牟莉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Johns Hopkins University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johns Hopkins University filed Critical Johns Hopkins University
Priority to CN201911163740.6A priority Critical patent/CN110981941A/zh
Publication of CN105431162A publication Critical patent/CN105431162A/zh
Application granted granted Critical
Publication of CN105431162B publication Critical patent/CN105431162B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nanotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
CN201480043222.XA 2013-06-07 2014-06-09 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台 Active CN105431162B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911163740.6A CN110981941A (zh) 2013-06-07 2014-06-09 生物模拟肽和生物可降解的递送平台

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361832290P 2013-06-07 2013-06-07
US61/832,290 2013-06-07
PCT/US2014/041526 WO2014197892A1 (en) 2013-06-07 2014-06-09 A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201911163740.6A Division CN110981941A (zh) 2013-06-07 2014-06-09 生物模拟肽和生物可降解的递送平台

Publications (2)

Publication Number Publication Date
CN105431162A CN105431162A (zh) 2016-03-23
CN105431162B true CN105431162B (zh) 2019-12-10

Family

ID=52008639

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201911163740.6A Pending CN110981941A (zh) 2013-06-07 2014-06-09 生物模拟肽和生物可降解的递送平台
CN201480043222.XA Active CN105431162B (zh) 2013-06-07 2014-06-09 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CN201911163740.6A Pending CN110981941A (zh) 2013-06-07 2014-06-09 生物模拟肽和生物可降解的递送平台

Country Status (11)

Country Link
US (4) US9802984B2 (enExample)
EP (2) EP3003343B1 (enExample)
JP (2) JP6470740B2 (enExample)
CN (2) CN110981941A (enExample)
AU (1) AU2014274703B2 (enExample)
CA (1) CA2914764C (enExample)
DK (1) DK3003343T3 (enExample)
ES (1) ES2774217T3 (enExample)
HU (1) HUE047735T2 (enExample)
IL (1) IL242760B (enExample)
WO (1) WO2014197892A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3003343B1 (en) * 2013-06-07 2019-10-23 The Johns Hopkins University A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases
WO2016022947A1 (en) 2014-08-07 2016-02-11 The Johns Hopkins University Nanoparticle modification of human adipose-derived mesenchymal stem cells for treating brain cancer and other neurological diseases
KR101748120B1 (ko) * 2015-07-13 2017-06-16 서울대학교산학협력단 나노입자-유리체 기반 단백질 복합체를 유효성분으로 포함하는 혈관신생억제용 조성물 및 이의 용도
CN108883150A (zh) * 2015-11-19 2018-11-23 阿斯克雷佩西治疗公司 具有抗血管生成、抗淋巴管生成以及消水肿性质的肽和纳米粒子制剂
BR112019006735A2 (pt) * 2016-10-04 2019-06-25 Asclepix Therapeutics Llc compostos e métodos para ativação da sinalização de tie2
WO2018208829A1 (en) * 2017-05-08 2018-11-15 Asclepix Therapeutics, Llc Biodegradable microparticles for sustained delivery of anti-angiogenic peptide
EP3661536A4 (en) * 2017-08-03 2021-07-21 Asclepix Therapeutics, Inc. PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR
US12059476B2 (en) 2017-10-10 2024-08-13 The Johns Hopkins University Biodegradable biomimetic particles
US11697804B2 (en) 2018-10-01 2023-07-11 The Johns Hopkins University Transcriptionally targeted and CpG-free plasmid for theranostic gene therapy
US12280157B2 (en) * 2019-02-06 2025-04-22 The University Of North Carolina At Chapel Hill Compositions and methods for inhibiting post-surgical adhesions
EA202192607A1 (ru) * 2019-03-26 2022-03-03 Асклепикс Терапьютикс, Инк. Композиции и способы для лечения глазного заболевания
CN113144213B (zh) * 2021-03-23 2023-04-07 西安交通大学医学院第一附属医院 一种多级pH响应基因-药物共递送的纳米药物、制备方法及其应用
WO2024044745A2 (en) * 2022-08-26 2024-02-29 Asclepix Therapeutics, Inc. Formulations for intraocular delivery of peptides derived from type iv collagen

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116278A2 (en) * 2006-03-31 2007-10-18 Istituto Nazionale Per La Ricerca Sul Cancro Antiangiogenic peptide and therapeutic uses thereof
WO2012079088A2 (en) * 2010-12-10 2012-06-14 The Johns Hopkins University Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2015781A4 (en) * 2005-09-12 2009-12-23 Univ Johns Hopkins COMPOSITIONS HAVING ANTIANGIOGENIC ACTIVITY AND USES THEREOF
AU2007239095B2 (en) * 2006-01-09 2012-05-03 The Regents Of The University Of California Immunostimulatory combinations for vaccine adjuvants
WO2008063932A2 (en) * 2006-11-10 2008-05-29 Genentech, Inc. Method for treating age-related macular degeneration
WO2008085828A2 (en) 2007-01-03 2008-07-17 The Johns Hopkins University Peptide modulators of angiogenesis and use thereof
JP2011519893A (ja) * 2008-05-06 2011-07-14 グラクソ グループ リミテッド 生物活性薬の封入
JP2011528566A (ja) * 2008-07-21 2011-11-24 コンプジェン リミティッド アンジオポエチン由来ペプチド
US9717694B2 (en) * 2009-05-15 2017-08-01 The Johns Hopkins University Peptide/particle delivery systems
JP2013514977A (ja) * 2009-12-16 2013-05-02 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 複数の物質の送達のための粒子
US20120192339A1 (en) 2010-07-28 2012-08-02 Honeywell International Inc. Flexible Body Armor Vest with Breast Plate
US20120270770A1 (en) 2010-08-03 2012-10-25 Jesse Michael Jaynes Anti-angiogenic peptides and their uses
US8877827B2 (en) 2011-02-24 2014-11-04 Konica Minolta, Inc. Active ray-curable inkjet ink, and image formation method
US12371522B2 (en) 2011-10-12 2025-07-29 The Johns Hopkins University Bioreducible poly (beta-amino ester)s for siRNA delivery
WO2014066898A1 (en) 2012-10-26 2014-05-01 The Johns Hopkins University A layer-by-layer approach to co-deliver dna and sirna via aunps: a potential platform for modifying release kinetics
EP3003343B1 (en) * 2013-06-07 2019-10-23 The Johns Hopkins University A biomimetic peptide and biodegradable delivery platform for the treatment of angiogenesis- and lymphangiogenesis-dependent diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116278A2 (en) * 2006-03-31 2007-10-18 Istituto Nazionale Per La Ricerca Sul Cancro Antiangiogenic peptide and therapeutic uses thereof
WO2012079088A2 (en) * 2010-12-10 2012-06-14 The Johns Hopkins University Mimetic peptides derived from collagen type iv and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Development of a biomimetic peptide derived from collagen IV with anti-angiogenic activity in breast cancer;Elena V. Rosca等;《Cancer Biology & Therapy》;20111101;第12卷(第9期);第1555-8576页 *
聚乳酸/羟基乙酸纳米粒的应用进展;容跃等;《临床超声医学杂志》;20110228;第13卷(第2期);第109-111页 *

Also Published As

Publication number Publication date
JP2016521712A (ja) 2016-07-25
CN105431162A (zh) 2016-03-23
ES2774217T3 (es) 2020-07-17
EP3643318A1 (en) 2020-04-29
US20200361993A1 (en) 2020-11-19
CA2914764C (en) 2021-10-26
AU2014274703A1 (en) 2015-12-10
US9802984B2 (en) 2017-10-31
EP3003343B1 (en) 2019-10-23
HK1222542A1 (zh) 2017-07-07
US10774112B2 (en) 2020-09-15
US11981754B2 (en) 2024-05-14
DK3003343T3 (da) 2020-02-03
EP3003343A4 (en) 2016-11-30
JP2019089790A (ja) 2019-06-13
IL242760B (en) 2021-03-25
HUE047735T2 (hu) 2020-05-28
EP3003343A1 (en) 2016-04-13
US20240391957A1 (en) 2024-11-28
CN110981941A (zh) 2020-04-10
WO2014197892A1 (en) 2014-12-11
CA2914764A1 (en) 2014-12-11
JP6470740B2 (ja) 2019-02-13
JP6931011B2 (ja) 2021-09-01
US20160122390A1 (en) 2016-05-05
US20180134753A1 (en) 2018-05-17
AU2014274703B2 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
CN105431162B (zh) 用于治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台
US11155603B2 (en) Mimetic peptides derived from collagen type IV and their use for treating angiogenesis- and lymphangiogenesis- dependent diseases
JP7530394B2 (ja) 血液脳関門を通過して輸送するための組成物及び方法
KR20190066040A (ko) Tie2 신호전달을 활성화시키기 위한 화합물 및 방법
KR20140142733A (ko) Egfl7 표적화 및/또는 결합 폴리펩타이드, 그리고 신생혈관생성을 저해하는 방법
US11674959B2 (en) Methods for identifying and preparing pharmaceutical agents for activating Tie1 and/or Tie2 receptors
HK40022338A (en) A biomimetic peptide and biodegradable delivery platform
HK1222542B (zh) 用於治疗血管生成依赖性和淋巴管生成依赖性疾病的生物模拟肽和生物可降解的递送平台

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1222542

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant